Published in Nature on April 04, 1991
Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology (2012) 10.00
Hepatitis B virus biology. Microbiol Mol Biol Rev (2000) 7.58
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A (1992) 5.94
Mycotoxins. Clin Microbiol Rev (2003) 5.59
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J (1996) 5.14
Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A (1998) 4.99
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A (1994) 3.76
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol (2008) 3.34
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 3.14
Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol (2013) 3.12
The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis (2011) 2.96
Cloning of the Aspergillus parasiticus apa-2 gene associated with the regulation of aflatoxin biosynthesis. Appl Environ Microbiol (1993) 2.57
Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer (1991) 2.52
Harnessing transposons for cancer gene discovery. Nat Rev Cancer (2010) 2.44
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42
Comparative mapping of aflatoxin pathway gene clusters in Aspergillus parasiticus and Aspergillus flavus. Appl Environ Microbiol (1995) 2.33
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest (1993) 2.25
Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut (2014) 2.19
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet (2015) 2.17
The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer (1994) 2.14
MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med (2008) 1.99
Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A (1993) 1.95
p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A (1993) 1.93
Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol (2010) 1.91
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
Serum markers of hepatocellular carcinoma. Dig Dis Sci (2010) 1.76
Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci U S A (1993) 1.71
Genetics of hepatocellular carcinoma. World J Gastroenterol (2007) 1.64
Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol (2010) 1.64
Non-viral causes of hepatocellular carcinoma. World J Gastroenterol (2010) 1.63
Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A (1997) 1.60
Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57
Requirement of LaeA for secondary metabolism and sclerotial production in Aspergillus flavus. Fungal Genet Biol (2008) 1.51
Methylation profiles reveal distinct subgroup of hepatocellular carcinoma patients with poor prognosis. PLoS One (2014) 1.51
EGFR mutation detection in NSCLC--assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch (2010) 1.45
Aspergillus has distinct fatty acid synthases for primary and secondary metabolism. Proc Natl Acad Sci U S A (1996) 1.45
Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res (2009) 1.44
The aflatoxin B(1) formamidopyrimidine adduct plays a major role in causing the types of mutations observed in human hepatocellular carcinoma. Proc Natl Acad Sci U S A (2002) 1.41
Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A (1995) 1.41
Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer (1992) 1.36
Mutation and cancer: the antecedents to our studies of adaptive mutation. Genetics (1998) 1.36
Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol (1996) 1.35
Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: the role of apurinic sites. Proc Natl Acad Sci U S A (1995) 1.35
Application of biologic markers to studies of environmental risks in children and the developing fetus. Environ Health Perspect (1995) 1.34
p53 Family and Cellular Stress Responses in Cancer. Front Oncol (2014) 1.33
An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1992) 1.33
Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol (1994) 1.30
Mutational properties of the primary aflatoxin B1-DNA adduct. Proc Natl Acad Sci U S A (1996) 1.29
The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer (1996) 1.28
Human hepatocyte carcinogenesis (review). Int J Oncol (2013) 1.28
Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A (1994) 1.28
Aspergillus nidulans mutants defective in stc gene cluster regulation. Genetics (1999) 1.28
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
The formation and biological significance of N7-guanine adducts. Mutat Res (2009) 1.21
Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J Biomed Biotechnol (2012) 1.20
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ (2014) 1.17
Tumourigenesis associated with the p53 tumour suppressor gene. Br J Cancer (1993) 1.16
Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. PLoS One (2013) 1.16
Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes (2010) 1.13
Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci U S A (1993) 1.13
Neoplasia of the ampulla of Vater. Ki-ras and p53 mutations. Am J Pathol (1993) 1.12
Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol (2008) 1.09
Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol Lett (2013) 1.08
Current understanding on aflatoxin biosynthesis and future perspective in reducing aflatoxin contamination. Toxins (Basel) (2012) 1.05
p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation. Br J Cancer (1998) 1.05
Liver cancer: Approaching a personalized care. J Hepatol (2015) 1.05
The clonal origin and clonal evolution of epithelial tumours. Int J Exp Pathol (2000) 1.04
p53 expression in colorectal adenomas. Am J Pathol (1993) 1.04
Hepatitis B virus infection and primary hepatocellular carcinoma. Clin Microbiol Rev (1992) 1.04
Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma. World J Gastroenterol (1998) 1.03
Database and software for the analysis of mutations at the human p53 gene. Nucleic Acids Res (1994) 1.03
Analysis of N-ras gene mutation and p53 gene expression in human hepatocellular carcinomas. World J Gastroenterol (1998) 1.02
Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc Natl Acad Sci U S A (1992) 1.02
AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res (2013) 1.01
Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks. World J Gastroenterol (1999) 1.01
Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer (2012) 1.01
The role of aflatoxins in hepatocellular carcinoma. Hepat Mon (2012) 1.01
Cancer genes. Telling changes of base. Nature (1991) 0.98
Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) (2005) 0.98
Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations. Br J Cancer (1999) 0.97
HCC, diet and metabolic factors: Diet and HCC. Hepat Mon (2011) 0.97
Singlet oxygen induced mutation spectrum in mammalian cells. Nucleic Acids Res (1992) 0.96
High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br J Cancer (1993) 0.96
Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer (2001) 0.96
Multiple genetic alterations in human carcinogenesis. Environ Health Perspect (1992) 0.95
Novel pattern of P53 mutation in breast cancers from Austrian women. J Clin Invest (1995) 0.95
p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritis. Arthritis Res Ther (2004) 0.95
Absence of mutation of the p73 gene localized at chromosome 1p36.3 in hepatocellular carcinoma. Br J Cancer (1999) 0.95
Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J Virol (2002) 0.95
p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ Health Perspect (1996) 0.94
Cigarette smoking and p53 mutations in lung cancer and bladder cancer. Environ Health Perspect (1996) 0.94
High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer (1996) 0.94
Modulation of apoptotic signaling by the hepatitis B virus X protein. Viruses (2012) 0.93
p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am J Pathol (1993) 0.93
Molecular epidemiology of aflatoxin exposures: validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans. Environ Health Perspect (1993) 0.92
Chemistry and structural biology of DNA damage and biological consequences. Chem Biodivers (2011) 0.92
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. J Cell Biol (1979) 4.86
PATIKA: an integrated visual environment for collaborative construction and analysis of cellular pathways. Bioinformatics (2002) 2.93
Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A (1990) 2.59
Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med (1990) 2.36
Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol (2000) 2.30
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet (1996) 2.26
The complications of trabeculectomy (a 20-year follow-up). Eye (Lond) (1990) 2.26
Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet (1988) 1.95
Liver damage in heatstroke. Am J Med (1970) 1.81
Hepatitis B virus and hepatocellular carcinoma. Int J Exp Pathol (2001) 1.59
Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res (2001) 1.57
In vivo gene electroinjection and expression in rat liver. FEBS Lett (1996) 1.53
Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma. Science (1985) 1.51
Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. Proc Natl Acad Sci U S A (1989) 1.34
Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res (1991) 1.30
Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci U S A (1994) 1.28
Annexin II up-regulates cellular levels of p11 protein by a post-translational mechanisms. Biochem J (1996) 1.24
Alpha-fetoprotein in primary liver cancer and other diseases. Gut (1974) 1.23
The major histocompatibility complex class I antigen-binding protein p88 is the product of the calnexin gene. Proc Natl Acad Sci U S A (1992) 1.22
Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology (1995) 1.22
Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene (1999) 1.21
Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene (2006) 1.15
Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines. FASEB J (1993) 1.12
Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene (2001) 1.07
Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma. Mol Cell Biol (1990) 1.03
The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene (1999) 1.02
Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res (1994) 1.02
The effect of organophosphate insecticide chlorpyrifos-ethyl on lipid peroxidation and antioxidant enzymes (in vitro). Arch Toxicol (2000) 1.02
Physiological studies of human chorionic gonadotropin (hCG), alpha hCG, and beta hCG as measured by specific monoclonal immunoradiometric assays. Endocrinology (1987) 1.00
Mutant hepatitis B viruses: a matter of academic interest only or a problem with far-reaching implications? Vaccine (2001) 1.00
Renal changes in cirrhosis. Gut (1972) 0.99
Depressed natural killer cell activity in patients with hepatocellular carcinoma. In vitro effects of interferon and levamisole. Cancer (1982) 0.98
Allele-specific PCR analysis of p53 codon 249 AGT transversion in liver tissues from patients with viral hepatitis. Int J Cancer (1996) 0.96
Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res (1998) 0.94
Anger attacks in depressed Turkish outpatients. Ann Clin Psychiatry (2000) 0.93
Enhanced expression of an exocrine pancreatic protein in Alzheimer's disease and the developing human brain. J Clin Invest (1990) 0.92
p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene (1993) 0.91
Recombinant leukocyte interferon treatment of chronic hepatitis B. Hepatology (1985) 0.91
In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells. Biochem Biophys Res Commun (2000) 0.90
Correlation of HBV DNA and monoclonal reactivity to HBsAg in serum of patients with HBV infection. J Virol Methods (1986) 0.90
A cellular gene up-regulated by hepatitis B virus-encoded X antigen promotes hepatocellular growth and survival. Hepatology (2001) 0.90
Precore/core mutations of hepatitis B virus in hepatocellular carcinomas developed on noncirrhotic livers. Gastroenterology (1996) 0.89
Genomic stability and wild-type p53 function of lymphoblastoid cells with germ-line p53 mutation. Oncogene (1995) 0.88
p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours. Oncogene (1997) 0.88
An unusual cause of ureteral obstruction in a renal transplant recipient: ureteric aspergilloma. Transplant Proc (2005) 0.87
Marked vitamin D deficiency in patients with diabetes in the UK: ethnic and seasonal differences and an association with dyslipidaemia. Diabet Med (2012) 0.87
In vivo localization of human colon adenocarcinoma by monoclonal antibody binding to a highly expressed cell surface antigen. Cancer Res (1988) 0.87
ras, p53 and HPV status in benign and malignant prostate tumors. Int J Cancer (1995) 0.87
Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Dig Dis Sci (2001) 0.86
Electrocardiographic changes in patients with ischaemic stroke and their prognostic importance. Int J Clin Pract (2004) 0.86
Identification of epitopes associated with hCG and the beta hCG carboxyl terminus by monoclonal antibodies produced against a synthetic peptide. J Immunol (1985) 0.86
Nail changes in connective tissue diseases: do nail changes provide clues for the diagnosis? J Eur Acad Dermatol Venereol (2007) 0.85
Thymidine dinucleotides induce S phase cell cycle arrest in addition to increased melanogenesis in human melanocytes. J Invest Dermatol (1998) 0.85
p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci U S A (1995) 0.85
Serum somatomedin and insulin levels in tumor hypoglycemia. J Endocrinol Invest (1978) 0.85
In vivo expression of two novel tumor-associated antigens and their use in immunolocalization of human hepatocellular carcinoma. Hepatology (1989) 0.85
Radioimmunolocation of hepatic and pulmonary metastasis of human colon adenocarcinoma. Gastroenterology (1989) 0.84
Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology (1996) 0.84
Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. Oncology (1987) 0.84
NAPO as a novel marker for apoptosis. J Cell Biol (2001) 0.84
Cell-surface changes associated with transformation of human hepatocytes to the malignant phenotype. Proc Natl Acad Sci U S A (1988) 0.84
Germline hMSH2 and hMLH1 gene mutations in incomplete HNPCC families. Int J Cancer (1997) 0.83
Thumbsucking and falling asleep. Br J Med Psychol (1977) 0.83
Sensitive and specific assay for human chorionic gonadotropin (hCG) based on anti-peptide and anti-hCG monoclonal antibodies: construction and clinical implications. J Clin Endocrinol Metab (1986) 0.83
Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. Oncogene (1994) 0.83
Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers. Int J Cancer (1995) 0.83
Evidence of a hereditary p53 syndrome in cancer-prone families. Int J Cancer (1996) 0.83
Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells. J Hepatol (2000) 0.83
c-fos and c-myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res (1991) 0.83
Analysis of airborne pollen fall in Nicosia (Cyprus). Environ Monit Assess (2012) 0.82
CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol (2005) 0.82
First-trimester maternal serum alpha-fetoprotein and human chorionic gonadotropin screening for chromosome defects. Prenat Diagn (1990) 0.81
Paraneoplastic extralimbic encephalitis associated with thymoma and myastenia gravis: three years follow up. Clin Neurol Neurosurg (2012) 0.81
The effect of long-term use of progesterone therapy on proliferation and apoptosis in simple endometrial hyperplasia without atypia. Int J Gynecol Cancer (2006) 0.81
Effect of transport on pulsatile LH release in ovariectomized ewes with or without prior steroid exposure at different times of year. J Reprod Fertil (1999) 0.81
Clinical significance of enhanced detection of HBsAg by a monoclonal radioimmunoassay. Hepatology (1984) 0.80
The diagnostic and prognostic significance of the serum enzyme changes in heatstroke. Trans R Soc Trop Med Hyg (1971) 0.80
Carpal tunnel syndrome in carpet workers. Int Arch Occup Environ Health (2001) 0.80
Gastric carcinoma in northwestern Turkey: epidemiologic characteristics. J Environ Pathol Toxicol Oncol (1993) 0.80
A monoclonal antibody against DNA binding helix of p53 protein. Oncogene (2001) 0.80
Alteration of p53 damage response by tamoxifen treatment. Clin Cancer Res (1996) 0.80
Synchronous ossiculoplasty with titanium prosthesis during canal wall down surgery for advanced cholesteatoma: anatomical and hearing outcomes. J Laryngol Otol (2011) 0.79
Comparison of total thyroidectomy, bilateral subtotal thyroidectomy and Dunhill operations in the treatment of benign thyroid disorders. Minerva Chir (2011) 0.79
The effects of cytokines on human chorionic gonadotropin (hCG) production by a trophoblast cell line. J Reprod Immunol (1993) 0.79
Assessment of information and education about topical corticosteroids in dermatology outpatient departments: experience from Turkey. J Eur Acad Dermatol Venereol (2003) 0.78
Lymphocyte subtypes in patients with atopic eczema, protein calorie malnutrition, SLE and liver disease. J Clin Lab Immunol (1983) 0.78
Expression of human alpha-actinin in human hepatocellular carcinoma. Cancer Res (1990) 0.78
Site-directed mutagenesis by fusion of contiguous DNA fragments. Biotechniques (1999) 0.78
Congenital dyserythropoietic anemia type I with ringed sideroblasts. Haematologia (Budap) (2000) 0.78